ATE404176T1 - Stabilisierte lyophilisierte zubereitungen mit gewebefaktor-inhibitor (tfpi) oder varianten des gewebefaktor-inhibitors - Google Patents

Stabilisierte lyophilisierte zubereitungen mit gewebefaktor-inhibitor (tfpi) oder varianten des gewebefaktor-inhibitors

Info

Publication number
ATE404176T1
ATE404176T1 AT04700827T AT04700827T ATE404176T1 AT E404176 T1 ATE404176 T1 AT E404176T1 AT 04700827 T AT04700827 T AT 04700827T AT 04700827 T AT04700827 T AT 04700827T AT E404176 T1 ATE404176 T1 AT E404176T1
Authority
AT
Austria
Prior art keywords
tissue factor
factor inhibitor
tfpi
variants
lyophilized preparations
Prior art date
Application number
AT04700827T
Other languages
English (en)
Inventor
Bao-Lu Chen
Maninder Hora
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE404176T1 publication Critical patent/ATE404176T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AT04700827T 2003-01-08 2004-01-08 Stabilisierte lyophilisierte zubereitungen mit gewebefaktor-inhibitor (tfpi) oder varianten des gewebefaktor-inhibitors ATE404176T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US43852403P 2003-01-08 2003-01-08
US49454703P 2003-08-13 2003-08-13
US50927603P 2003-10-08 2003-10-08
US51209203P 2003-10-20 2003-10-20

Publications (1)

Publication Number Publication Date
ATE404176T1 true ATE404176T1 (de) 2008-08-15

Family

ID=32719507

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04700827T ATE404176T1 (de) 2003-01-08 2004-01-08 Stabilisierte lyophilisierte zubereitungen mit gewebefaktor-inhibitor (tfpi) oder varianten des gewebefaktor-inhibitors

Country Status (9)

Country Link
US (2) US20040180827A1 (de)
EP (1) EP1589949B1 (de)
JP (1) JP2008500942A (de)
AT (1) ATE404176T1 (de)
CA (1) CA2512680A1 (de)
DE (1) DE602004015725D1 (de)
ES (1) ES2311789T3 (de)
PT (1) PT1589949E (de)
WO (1) WO2004062646A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
CA2488558C (en) 2002-06-07 2013-08-20 Dyax Corp. Prevention and reduction of blood loss
DK2386310T3 (en) 2002-08-28 2019-02-25 Dyax Corp Methods of preserving organs and tissues
US20050032153A1 (en) * 2003-04-30 2005-02-10 Ropp Philip A. Control of cyanate in aqueous urea solutions by non-1,2-ethylene diamine like compounds for the protection of protein/peptide carbamylation
EP2311871A3 (de) * 2004-08-17 2012-08-08 Regeneron Pharmaceuticals, Inc. IL-1 Antagonisten enthaltende flüssige stabile Zusammensetzung
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2006081320A2 (en) * 2005-01-27 2006-08-03 Human Genome Sciences, Inc. Pharmaceutical formulation
GB0517688D0 (en) * 2005-08-31 2005-10-05 Cambridge Biostability Ltd Improvements in the stabilisation of biological materials
GB2430880A (en) * 2005-10-04 2007-04-11 Cambridge Biostability Ltd Pharmaceutical compositions stabilized in glassy particles
GB0523638D0 (en) * 2005-11-21 2005-12-28 Cambridge Biostability Ltd Pharmaceutical device for the administration of substances to patients
WO2007103425A2 (en) * 2006-03-06 2007-09-13 Novartis Ag Kits and methods for preparing pharmaceutical compositions comprising tissue factor pathway inhibitor (tfpi)
WO2007106746A2 (en) * 2006-03-10 2007-09-20 Dyax Corp. Formulations for ecallantide
WO2010080833A1 (en) 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
SI2521568T1 (sl) 2010-01-06 2019-01-31 Dyax Corp. Proteini, ki vežejo plazemski kalikrein
IL269565B2 (en) 2011-01-06 2024-06-01 Dyax Corp KALLIKREIN PLASMA BINDING PROTEINS
CN102942597A (zh) * 2012-10-24 2013-02-27 江苏大学 含氯或氟的五配位咔咯钴配合物及其合成方法
BR112016022318A2 (pt) 2014-03-27 2017-10-31 Dyax Corp método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo
EA036091B1 (ru) * 2014-08-20 2020-09-25 Портола Фармасьютикалз, Инк. ВОДНЫЕ СОСТАВЫ АНТИДОТОВ ФАКТОРА Xa (fXa) ДЛЯ ПРЕДУПРЕЖДЕНИЯ ИЛИ УМЕНЬШЕНИЯ КРОВОТЕЧЕНИЯ И ИХ ПРИМЕНЕНИЕ
JP7003354B2 (ja) 2015-12-11 2022-03-04 武田薬品工業株式会社 遺伝性血管性浮腫の発作を治療するための血漿カリクレイン阻害薬およびその用途
WO2017147522A1 (en) 2016-02-24 2017-08-31 Portola Pharmaceuticals, Inc. Lyophilized formulations for factor xa antidote
MX2020004936A (es) * 2017-11-16 2020-08-27 Amgen Inc Composiciones estables de compuestos de carfilzomib pegilado.

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US4966852A (en) * 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
US5219994A (en) * 1988-11-08 1993-06-15 W. Alton Jones Cell Science Center, Inc. Inhibitor of tissue factor activity
DK408089D0 (da) * 1989-08-18 1989-08-18 Novo Nordisk As Proteiner
US5583107A (en) * 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US5276015A (en) * 1992-03-18 1994-01-04 Washington University Method of inhibiting microvascular thrombosis
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
JP3435946B2 (ja) * 1994-12-21 2003-08-11 王子製紙株式会社 耐熱性キシラナーゼ
ATE251141T1 (de) * 1995-03-10 2003-10-15 Berlex Lab Benzamidin-derivate, deren herstellung und deren verwendung als anti-koagulantien
PT1602667E (pt) * 1995-06-07 2007-07-13 Searle Llc Formulação aquosa que compreende tfpi e agentes de solubilização
ATE239501T1 (de) * 1995-06-07 2003-05-15 Chiron Corp Regulierung der neutrophil elastase synthese und freisetzung
US5919765A (en) * 1995-06-07 1999-07-06 Cor Therapeutics, Inc. Inhibitors of factor XA
US5888968A (en) * 1995-06-07 1999-03-30 Chiron Corporation TFPI formulation
US5721214A (en) * 1995-06-07 1998-02-24 Cor Therapeutics, Inc. Inhibitors of factor Xa
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5580107A (en) * 1995-09-25 1996-12-03 Dell U.S.A., L.P. Hidden latch hook for portable personal computer and the like
US5736364A (en) * 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
US5824660A (en) * 1996-06-10 1998-10-20 G. D. Searle & Co. Method of inhibiting glomerulonephritis
US6262233B1 (en) * 1997-01-31 2001-07-17 Human Genome Sciences, Inc. Tissue factor pathway inhibitor-3
WO2001024814A1 (en) * 1999-10-04 2001-04-12 Chiron Corporation Stabilized liquid polypeptide-containing pharmaceutical compositions
PL356641A1 (en) * 1999-12-30 2004-06-28 Chiron Corporation Methods for pulmonary delivery of interleukin-2
DE10022092A1 (de) * 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
KR20040040489A (ko) * 2001-10-15 2004-05-12 카이론 코포레이션 조직 인자 경로 억제제（ｔｆｐｉ）의 저용량 투여에 의한패혈증의 치료

Also Published As

Publication number Publication date
CA2512680A1 (en) 2004-07-29
DE602004015725D1 (de) 2008-09-25
PT1589949E (pt) 2008-11-06
WO2004062646A1 (en) 2004-07-29
US20060159679A1 (en) 2006-07-20
ES2311789T3 (es) 2009-02-16
US20040180827A1 (en) 2004-09-16
EP1589949A1 (de) 2005-11-02
JP2008500942A (ja) 2008-01-17
EP1589949B1 (de) 2008-08-13
WO2004062646A9 (en) 2010-11-11

Similar Documents

Publication Publication Date Title
ATE404176T1 (de) Stabilisierte lyophilisierte zubereitungen mit gewebefaktor-inhibitor (tfpi) oder varianten des gewebefaktor-inhibitors
NO20044406L (no) Stabilisert flytende farmasoytisk sammensetning samt fremgangsmate for a oke stabiliteten av IL-2
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
PE20040972A1 (es) Intermedio de formulacion aceptablemente no higroscopico que comprende un farmaco higroscopico
PE84899A1 (es) Formulaciones farmaceuticas que contienen voriconazol
WO2007019232A3 (en) Immunoconjugate formulations
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
RS53945B1 (en) SUPER FAST INSULIN COMPOSITIONS
IL208697A0 (en) Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol
SE0301886D0 (sv) New use V
UY28897A1 (es) Ácido 2-((2-(2-metilaminopirimidin-4-il)-1h-indol-5-carbonil)amino)-3-(fenilpiridin-2-ilamino)propiónico sustancialmente puro como inhibidor de la cinasa ikb
DK1273299T3 (da) Minoxidilinindeholdende praparater
AR038927A1 (es) Sales de acido organico
DE60224449D1 (de) Gebrauchsfertige paracetamol injektionslösungen enthaltend propylenglykol als einziges cosolvens
HUP0101899A2 (hu) Cisztein-aktivitástól függő enzimeket gátló hatású tiadiazolvegyületek, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
BRPI0302496B8 (pt) composições farmacêuticas com atividade antibiótica
NO20004306D0 (no) Farmasøytiske sammensetninger som inneholder fosfolipaseinhibitoren natrium[[3-(2-amino-1,2-dioksoetyl-1- fenylmetyl)-1H-indol-4-yl]oksy)acetat
RU2012122793A (ru) Композиция, способ и набор для альфа-1 ингибитора протеазы
DE60236025D1 (de) Pharmazeutische zusammensetzung enthaltend l-arginin
SE0004101D0 (sv) New use
EP1803445A3 (de) Stabilisierte lyophilisierte Zubereitungen mit Gewebefaktor-Inhibitor (TFPI) oder Varianten des Gewebefaktor-Inhibitors
PE20240361A1 (es) Composicion farmaceutica acuosa de levilimab y su uso
MXPA04005033A (es) Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.
PE20040537A1 (es) Fitasas modificadas
BRPI0412453A (pt) uso do ácido ascórbico ou um sal fisiologicamente aceitável do mesmo

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1589949

Country of ref document: EP

REN Ceased due to non-payment of the annual fee